Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
49 studies found for:    triple negative breast cancer | Phase 3, 4
Show Display Options
Rank Status Study
1 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Condition: Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Nab-Paclitaxel;   Drug: Placebo
2 Active, not recruiting Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Biological: pembrolizumab;   Drug: capecitabine;   Drug: eribulin;   Drug: gemcitabine;   Drug: vinorelbine
3 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Normale Saline Solution
4 Not yet recruiting PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy
Conditions: Breast Cancer;   Brain Metastasis
Intervention: Radiation: prophylactic cranial irradiation
5 Active, not recruiting Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Zoledronic acid
6 Not yet recruiting A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: carboplatin
7 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
8 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Condition: Triple Negative Breast Neoplasms
Interventions: Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Placebo
9 Recruiting Huaier Granule in Treating Women With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Huaier Granule
10 Active, not recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
11 Recruiting Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Interventions: Drug: TPC;   Drug: Bicalutamide 150 mg
12 Not yet recruiting A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Atezolizumab Placebo;   Drug: Paclitaxel
13 Recruiting A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Condition: Triple-Negative Breast Cancer
Interventions: Drug: EndoTAG-1;   Drug: Paclitaxel;   Drug: Gemcitabine Hydrochloride
14 Active, not recruiting Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: 5-Fu/epirubicin/CTX following Docetaxel;   Drug: Docetaxel/capecitabine followed by XEC
15 Recruiting Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: MSB0010718C
16 Recruiting Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
Condition: Breast Cancer
Interventions: Drug: taxane plus carboplatin;   Drug: Taxane
17 Recruiting Adjuvant Treatment of EC Followed by wP and wPCb in Triple-Negative Breast Cancer
Condition: Breast Neoplasm
Interventions: Drug: Epirubicin plus Cyclophosphamide;   Drug: Paclitaxel;   Drug: Paclitaxel plus Carboplatin
18 Completed Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Gemcitabine,cisplatin;   Drug: Gemcitabine, Paclitaxel
19 Recruiting Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Placebo;   Drug: Paclitaxel
20 Recruiting Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Condition: Invasive Ductal Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Abraxane;   Drug: MPDL3280A;   Procedure: Surgery;   Drug: Anthra

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.